← Leaderboards
Carlo Giovanni Traverso
Massachusetts Institute Of Technology
$2,090,286
Attributed
$4,180,572
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2018–21$2M$1.5M$1M$500K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$4,180,572 · 1
By mechanism
R01$4,180,572 · 1
Top collaborators
- Robert S Langer4 shared
Most similar at Massachusetts Institute Of Technology
Same institution · by research overlap
- Robert S Langer$47,407,448
- Linda G. Griffith$21,069,415
- Daniela M Dinulescu$2,065,033
- Bernhardt L Trout$2,914,875
- Michael J Mitchell$3,277,478
Others in their field
Other Emerging Leaders on “Enteroendocrine Cell”
- Nicolas Buchon · Cornell University$5,465,626
- Christopher Eldridge Sims · Altis Biosystems, Inc.$2,598,964
- Lisa R Beutler · Northwestern University$1,907,974
- Martin Beinborn · Velum, Inc.$1,900,024
- Edward Phelps · University Of Florida$1,784,458
- Andres J Acosta · Mayo Clinic Rochester$979,654
Research focus
Enteroendocrine CellAdherenceAbattoirsBaseBenchmarkingBiological AvailabilityBiological ProductsAbsorptionCellsCell TypeClassificationComplexCostCoupledDesignDeveloped CountriesBiologyAnimal ModelDrug CombinationsDrug Delivery SystemsDrug DevelopmentDrug FormulationsDrug ModelingsEpidemic
Grant awards (4)
A new high-throughput gastrointestinal tract explant platform for drug formulation discovery and metabolic disease modulation$1,068,674
R01 · FY2021 · EB
A new high-throughput gastrointestinal tract explant platform for drug formulation discovery and metabolic disease modulation$1,057,438
R01 · FY2020 · EB
A new high-throughput gastrointestinal tract explant platform for drug formulation discovery and metabolic disease modulation$1,030,151
R01 · FY2019 · EB
A new high-throughput gastrointestinal tract explant platform for drug formulation discovery and metabolic disease modulation$1,024,309
R01 · FY2018 · EB